Analysts Issue Forecasts for ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities research analysts at Zacks Research increased their Q2 2026 earnings estimates for ResMed in a report issued on Thursday, January 8th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $2.66 per share for the quarter, up from their prior estimate of $2.63. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q3 2026 earnings at $2.69 EPS, Q4 2026 earnings at $2.71 EPS, FY2026 earnings at $10.62 EPS, Q1 2027 earnings at $2.63 EPS, Q2 2027 earnings at $2.73 EPS, Q3 2027 earnings at $2.83 EPS, Q4 2027 earnings at $3.01 EPS, FY2027 earnings at $11.20 EPS, Q1 2028 earnings at $3.11 EPS, Q2 2028 earnings at $3.14 EPS and FY2028 earnings at $12.80 EPS.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The firm had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the firm posted $2.20 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year.

Several other research analysts also recently commented on the company. Robert W. Baird reaffirmed a “neutral” rating and issued a $275.00 price objective (down previously from $300.00) on shares of ResMed in a research note on Tuesday, December 16th. Mizuho reduced their target price on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Citigroup assumed coverage on shares of ResMed in a report on Thursday, September 18th. They set a “buy” rating and a $330.00 price target on the stock. UBS Group reiterated a “buy” rating and issued a $345.00 price target on shares of ResMed in a research report on Friday, December 12th. Finally, Baird R W downgraded shares of ResMed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $296.09.

ResMed Price Performance

NYSE RMD opened at $254.89 on Monday. The business’s fifty day moving average is $248.80 and its 200 day moving average is $263.25. ResMed has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. The company has a market capitalization of $37.20 billion, a PE ratio of 26.09, a price-to-earnings-growth ratio of 1.74 and a beta of 0.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. SJS Investment Consulting Inc. raised its stake in ResMed by 1,433.3% during the third quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 86 shares in the last quarter. Imprint Wealth LLC bought a new stake in shares of ResMed in the 3rd quarter worth about $26,000. WFA of San Diego LLC purchased a new stake in shares of ResMed during the 2nd quarter valued at about $26,000. Sunbelt Securities Inc. bought a new position in shares of ResMed in the 3rd quarter valued at about $31,000. Finally, Westside Investment Management Inc. grew its position in ResMed by 100.0% in the third quarter. Westside Investment Management Inc. now owns 132 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 66 shares in the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ResMed

In other ResMed news, Director Witte Jan De sold 2,055 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total transaction of $524,025.00. Following the completion of the transaction, the director owned 4,261 shares in the company, valued at $1,086,555. This trade represents a 32.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $248.46, for a total value of $1,240,063.86. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $115,837,766.58. The trade was a 1.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 21,594 shares of company stock worth $5,403,495. Insiders own 0.65% of the company’s stock.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, November 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, November 13th. ResMed’s dividend payout ratio (DPR) is presently 24.56%.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.